Lake Street analyst Brooks O’Neil maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) today and set a price target of $60.00. The company’s shares closed yesterday at $27.11.
According to TipRanks, O’Neil is a 3-star analyst with an average return of 1.0% and a 46.83% success rate. O’Neil covers the Healthcare sector, focusing on stocks such as Astrana Health, Tandem Diabetes Care, and Harrow Health.
In addition to Lake Street, Tandem Diabetes Care also received a Buy from Craig-Hallum’s Alexander Nowak in a report issued yesterday. However, on February 22, Stifel Nicolaus maintained a Hold rating on Tandem Diabetes Care (NASDAQ: TNDM).
See Insiders’ Hot Stocks on TipRanks >>
TNDM market cap is currently $2.04B and has a P/E ratio of -7.89.
Based on the recent corporate insider activity of 99 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNDM in relation to earlier this year. Most recently, in January 2024, Rajwant Sodhi, a Director at TNDM bought 1,070.00 shares for a total of $29,596.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care (TNDM) Company Description:
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Read More on TNDM:
- Tandem Diabetes announces private placement of $250M in convertible senior notes
- Tandem Diabetes (NASDAQ:TNDM): Investors Look to Innovation to Drive the Stock Higher
- Tandem Diabetes sees Q1 revenue $175M, consensus $186.09M
- Tandem Diabetes sees FY24 non-GAAP revenue roughly $850M, consensus $842.49M
- Tandem Diabetes reports Q4 adjusted EPS (46c), consensus (25c)
